Last reviewed 2026-05-14 · How we verify

fIPV (0.2mL) IM

Centers for Disease Control and Prevention · FDA-approved active Biologic

fIPV (0.2mL) IM is a Inactivated viral vaccine Biologic drug developed by Centers for Disease Control and Prevention. It is currently FDA-approved for Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3.

fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing polio infection.

fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing polio infection. Used for Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3.

At a glance

Generic name	fIPV (0.2mL) IM
Sponsor	Centers for Disease Control and Prevention
Drug class	Inactivated viral vaccine
Modality	Biologic
Therapeutic area	Immunology / Infectious Disease
Phase	FDA-approved

Mechanism of action

fIPV contains chemically inactivated (killed) poliovirus particles of serotypes 1, 2, and 3. When administered intramuscularly, it triggers both humoral (antibody) and cellular immune responses without causing disease. The vaccine induces production of neutralizing antibodies that protect against infection if the vaccinated individual is exposed to wild-type or vaccine-derived poliovirus.

Approved indications

Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3

Common side effects

Injection site soreness, redness, or swelling
Fever
Irritability or fussiness
Drowsiness

Key clinical trials

Immunogenicity of Intramuscular and Intradermal IPV (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

fIPV (0.2mL) IM CI brief — competitive landscape report
fIPV (0.2mL) IM updates RSS · CI watch RSS
Centers for Disease Control and Prevention portfolio CI

Frequently asked questions about fIPV (0.2mL) IM

What is fIPV (0.2mL) IM?

fIPV (0.2mL) IM is a Inactivated viral vaccine drug developed by Centers for Disease Control and Prevention, indicated for Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3.

How does fIPV (0.2mL) IM work?

fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing polio infection.

What is fIPV (0.2mL) IM used for?

fIPV (0.2mL) IM is indicated for Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3.

Who makes fIPV (0.2mL) IM?

fIPV (0.2mL) IM is developed and marketed by Centers for Disease Control and Prevention (see full Centers for Disease Control and Prevention pipeline at /company/centers-for-disease-control-and-prevention).

What drug class is fIPV (0.2mL) IM in?

fIPV (0.2mL) IM belongs to the Inactivated viral vaccine class. See all Inactivated viral vaccine drugs at /class/inactivated-viral-vaccine.

What development phase is fIPV (0.2mL) IM in?

fIPV (0.2mL) IM is FDA-approved (marketed).

What are the side effects of fIPV (0.2mL) IM?

Common side effects of fIPV (0.2mL) IM include Injection site soreness, redness, or swelling, Fever, Irritability or fussiness, Drowsiness.

Drug class: All Inactivated viral vaccine drugs
Manufacturer: Centers for Disease Control and Prevention — full pipeline
Therapeutic area: All drugs in Immunology / Infectious Disease
Indication: Drugs for Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing